Alpelisib

Definition

An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.

NCIT:C94214 · NCI Thesaurus OBO Edition · CC BY 4.0

Also known as ALPELISIB, BYL 719, BYL-719, BYL719, Phosphoinositide 3-kinase Inhibitor BYL719, Piqray, VIJOICE — per NCIT

Also identified as

ATC L01EM03 per RXNORM
NCIT NCIT:C94214 per NCIT
SCTID 788050002 per RXNORM
SCTID 788079009 per RXNORM
UNII 08W5N2C97Q per RXNORM

Indications

Disease	Relation	Source
Breast neoplasm	may treat	MEDRT · Public domain (U.S. Government work)
Male breast carcinoma	may treat	MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ	Side effect / interaction	Source
Breast	may treat a disease of this organ	DERIVED · CC BY 4.0
Male breast	may treat a disease of this organ	DERIVED · CC BY 4.0

2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.